



# FOR ANY & EVERY LOOK

**Your expertise, meets ours.** The world's most diverse range of fillers and skinboosters.\*<sup>1-11</sup> Each and every one individually engineered so you can bring bespoke looks to life with precision.<sup>12,13</sup> Matching your mastery, with their vision.

\* The Restylane® product family has a broader range in G' (elastic modulus) than Juvéderm®, Belotero®, and Teosyal®.<sup>12</sup> G' is a measure of gel firmness (resistance to deformation), which can be used to understand how a gel's physical properties relate to its in vivo performance.<sup>12</sup>

*Restylane*<sup>®</sup>  
by GALDERMA

# THE WORLD'S MOST DIVERSE RANGE OF FILLERS AND SKINBOOSTERS<sup>3-11, 14, 15</sup>

**YOUR EXPERTISE, MEETS OURS.** WITH RESTYLANE, YOU CAN TRUST OUR **HIGH PERFORMANCE AND PROVEN SAFETY OVER 26 YEARS** TO HELP YOU DELIVER YOUR PATIENTS' VISION WITH PRECISION.<sup>23,24</sup>



## 1 CLOSEST TO NATURAL HA

THE ORIGINAL HA FILLER WITH MINIMAL MODIFICATION - CLOSEST TO SKIN'S OWN HA FOR INDIVIDUALIZED AND NATURAL-LOOKING RESULTS<sup>12,16-20</sup>



Restylane® owns the patent for the HA stabilization technique that results in a **minimally modified version of natural HA**, resulting in gels that are closer to the composition of natural HA<sup>17,18</sup>

## 4 PROVEN SAFETY

UNMATCHED 26 YEARS OF PROVEN SAFETY FOR DIVERSE SKIN COLORS AND TYPES<sup>§123,26,28,29</sup>



Restylane products have demonstrated potentially **lower risk of late-onset complications**<sup>‡30</sup>

Restylane HA fillers may be associated with a **lower incidence of nodule formation and inflammatory events** compared with Juvéderm® Volbella® and Juvéderm Voluma®<sup>‡30</sup>

Published safety data for Restylane includes nearly **407,000 patients of diverse skin colors and types**<sup>23,26,28,29</sup>

## 2 HIGH PERFORMANCE

LESS PRODUCT FOR GREAT EFFECT<sup>21,22</sup>

**Less product is needed** to achieve the desired result giving more controlled outcomes:<sup>21,22</sup>

- Restylane Kysse™ vs Juvéderm® Volbella® - **20% less**<sup>\*,\*\*21</sup>
- Restylane Volyme™ vs. Juvéderm® Voluma® - **13% less**<sup>†22</sup>

LONG DURATION

Fillers from the Restylane range achieve **results that last up to 24 months** with one retreatment depending on the product used and area treated<sup>‡23,24</sup>

## 5 HIGH PATIENT SATISFACTION ACROSS 26 YEARS<sup>27,31</sup>

26 YEARS OF EXPERIENCE AND TRUSTED WITH MORE THAN 55 MILLION TREATMENTS WORLDWIDE<sup>27</sup>



**Patient satisfaction was 95.9% or higher** at one month in 10 out of 13 Restylane studies across 26 years<sup>§31</sup>

**99% of patients would recommend a treatment** with Restylane to a friend<sup>32</sup>

**97% of patients showed improvements for up to 18 months** with one retreatment<sup>33</sup>

## 3 EXPERTS IN FACIAL DYNAMICS

THE FIRST HA FILLERS CLINICALLY PROVEN TO HAVE POSITIVE EFFECTS ON THE NATURALNESS OF DYNAMIC FACIAL EXPRESSIONS<sup>20,25</sup>



**Reduce the amount of strain** during dynamic facial expression and **restore youthful expression**<sup>25</sup>

\* Restylane Kysse (n=31) or Juvéderm® Volbella® (n=29) to treat the lips.<sup>18</sup> Total volumes injected at initial treatment and touch-up, and volumes injected at optional retreatment were reported.<sup>21</sup> A smaller total volume of study product was required in the Restylane Kysse group than in the Juvéderm® Volbella® group (1.54 ml vs. 1.94 ml in both lips together, P<0.001) to achieve optimal correction of lip fullness.<sup>21</sup>  
 \*\* In a 40-week, randomized, controlled, evaluator-blinded study, 270 patients received Restylane Kysse (n=183) or Juvéderm® Volbella® (n=87) to treat the lips and perioral area.<sup>34</sup> The mean volume injected in the lips was 1.82 ml (Restylane Kysse) and 2.24 ml (Juvéderm® Volbella®); P<0.001.<sup>34</sup>  
 † In a 48-week, randomized clinical study, patients received Restylane Volyme (n=142) or Juvéderm® Voluma® (n=68) as control, to address the cheeks/mid-face.<sup>22</sup> The mean total volumes injected at initial treatment and touch-up were reported. Patients treated with Restylane Volyme (N=141) required less total volume injected to achieve optimal aesthetic results compared with Juvéderm® Voluma® (N=68; 4.26 ml vs. 4.88 ml, P=0.0134).<sup>22</sup>  
 ‡ A second treatment (retreatment) was performed at 12 months in the same areas with the same products.<sup>23</sup> Touch-up was allowed 1 month after both treatments.<sup>23</sup>  
 § Restylane injectable gel was first approved for marketing and sale in September 1996 in the EU.<sup>27</sup>  
 ¶ Based on a Restylane publications analysis conducted in June 2021.<sup>26</sup> Sources include a published post-marketing safety study of 638 patients and a retrospective analysis of AE reports encompassing 406,000 patients.<sup>26</sup>  
 †† In a recent post-marketing safety surveillance study using the MAUDE database to assess delayed (≥14 days post-treatment) AEs of interest (inflammatory and noninflammatory nodules, hypersensitivity, granulomas), Restylane Refyne and Restylane Defyne both had fewer combined total events of interest vs. Juvéderm® Volbella® and Juvéderm® Voluma®.<sup>30</sup>  
 ‡‡ 95.9%. Based on an analysis of 13 clinical studies assessing subject satisfaction (as measured by GAIS) in patients treated with different OBT and NASHA fillers in varying facial areas. Analysis conducted in June 2021.<sup>31</sup>

AE, adverse event; EU, European Union; GAIS, Global Aesthetic Improvement Scale; HA, hyaluronic acid; MAUDE, Manufacturer and User Facility Device Experience; NASHA, Non-Animal Stabilized Hyaluronic Acid; OBT, Optimal Balance Technology.

# Restylane THE HA FILLER WITH THE LONGEST HISTORY

OF **PROVEN CLINICAL SAFETY** SUPPORTED BY A SCIENTIFIC HERITAGE<sup>26,27</sup>

## RESTYLANE PIONEERED THE ORIGINAL HA FILLER,<sup>\*27</sup> AND HAS A SCIENTIFIC HERITAGE BUILT ON:

- Over **26 years** of manufacturing experience and counting<sup>\*27</sup>
- Over **160 clinical publications**<sup>\*\*26</sup>
- Safety data collected from **20 sponsored trials**<sup>26</sup>
- Restylane has been cited in more than **370 publications**<sup>35</sup>
- HCP trust demonstrated in more than **55 million treatments** worldwide<sup>†27</sup>



OFFER YOUR PATIENTS CONFIDENCE WITH THE  
**UNMATCHED HERITAGE** OF RESTYLANE HA FILLERS<sup>26,27</sup>



## RESTYLANE OFFERS AN UNMATCHED 26 YEARS OF PROVEN SAFETY, INCLUDING ACROSS DIVERSE SKIN COLORS, TONES, AND TYPES<sup>\*,\*\*23,26-29</sup>

- Published safety data for Restylane products has reported results for nearly **407,000 patients**<sup>\*\*26</sup>



## AFTER THE USE OF **55 MILLION TREATMENTS OF RESTYLANE FILLERS**, **NO NEW OR UNEXPECTED ADVERSE EVENTS WERE REPORTED**<sup>†27,36</sup>



## RESTYLANE GELS CAN BE READILY DEGRADED USING HYALURONIDASE TO ALLOW FOR SAFE REMOVAL<sup>37</sup>

- Due to minimal HA crosslinking, **NASHA® gels dissolve more quickly** than HA gels with a greater degree of modification<sup>‡37</sup>

## RESTYLANE PRODUCTS HAVE DEMONSTRATED A LOWER RISK OF LATE-ONSET COMPLICATIONS COMPARED WITH JUVÉDERM® PRODUCTS<sup>30,38</sup>

- Compared with Juvéderm® Volbella® and Juvéderm® Voluma®, currently approved Restylane HA fillers are associated with a **lower incidence of nodule formation and inflammatory events**<sup>§||30,38</sup>

\* Restylane injectable gel was first approved for marketing and sale in September 1996 in the EU.<sup>27</sup>

\*\* Based on a Restylane publications analysis conducted in June 2021.<sup>26</sup> Sources include a published post-marketing safety study of 638 patients and a retrospective analysis of AE reports encompassing 406,000 patients.<sup>26</sup>

† Restylane products have been used in over 55 million aesthetic treatments worldwide since market introduction of Restylane in 1996.<sup>27</sup>

‡ For hyaluronidase to dissolve a HA filler, it must be able to access the intramolecular bonds within the HA. Factors affecting this access include the number of crosslinks between HA molecules and HA concentration. The more crosslinking, the more difficult it is for hyaluronidase to access its binding sites inside the HA filler. For this reason, HA fillers with extensive crosslinking require a long time to dissolve with hyaluronidase.<sup>37</sup>

§ In a recent post-marketing safety surveillance study using the MAUDE database to assess delayed (≥14 days post treatment) AEs of interest (inflammatory and noninflammatory nodules, hypersensitivity, granulomas), Restylane Refyne™, Restylane Defyne™, and Restylane Kysse™ each had fewer combined total events of interest vs. Juvéderm® Volbella® and Juvéderm® Voluma®.<sup>30</sup>

|| In a retrospective chart review, the incidence of delayed nodules in all patients who had received Juvéderm® Vycross® fillers during a 12-month period was assessed (1250 treatments in 1029 patients).<sup>38</sup> Compared with the FDA Summary of Safety and Effectiveness Data for NASHA fillers, Juvéderm® Volbella® was associated with a higher incidence of nodule formation.<sup>38</sup>

AE, adverse event; EU, European Union; FDA, Food and Drug Administration; HA, hyaluronic acid; MAUDE, Manufacturer and User Facility Device Experience; NASHA, Non-Animal Stabilized Hyaluronic Acid.



# THE WORLD'S MOST DIVERSE RANGE OF FILLERS AND SKINBOOSTERS

FOR BESPOKE, NATURAL-LOOKING RESULTS<sup>1-12,39</sup>

EACH AND EVERY PRODUCT IN OUR RANGE OF FILLERS AND SKINBOOSTERS IS **INDIVIDUALLY ENGINEERED** FOR A DIFFERENT PURPOSE, **SO THAT YOU CAN CREATE A LOOK TAILORED TO EACH PATIENT.**<sup>1,2,12,39</sup>

WITH DIFFERENT TECHNOLOGIES SUITED FOR EACH TREATMENT AREA, YOU CAN CRAFT TREATMENTS TO **LEAVE YOUR PATIENTS FILLED WITH CONFIDENCE.**<sup>12, 39-41</sup>

1 SKIN QUALITY<sup>10,11</sup>

RESTYLANE<sup>®</sup>  
SKINBOOSTERS<sup>™</sup>

2 TEAR TROUGHS<sup>5</sup>

RESTYLANE<sup>®</sup>

3 TEMPLES<sup>7</sup>

RESTYLANE<sup>®</sup>  
VOLYME<sup>™</sup>

4 CHEEKS<sup>3,7</sup>

RESTYLANE<sup>®</sup>  
LYFT<sup>™</sup>    RESTYLANE<sup>®</sup>  
VOLYME<sup>™</sup>

5 NOSE<sup>3</sup>

RESTYLANE<sup>®</sup>  
LYFT<sup>™</sup>

6 NASOLABIAL FOLDS<sup>4,6,9</sup>

RESTYLANE<sup>®</sup>    RESTYLANE<sup>®</sup>  
DEFYNE<sup>™</sup>    RESTYLANE<sup>®</sup>  
REFYNE<sup>™</sup>

7 PERIORAL LINES<sup>9</sup>

RESTYLANE<sup>®</sup>  
REFYNE<sup>™</sup>

8 MARIONETTE LINES<sup>4,9</sup>

RESTYLANE<sup>®</sup>    RESTYLANE<sup>®</sup>  
REFYNE<sup>™</sup>

9 LIPS<sup>8</sup>

RESTYLANE<sup>®</sup>  
KYSSE<sup>™</sup>

10 JAWLINE<sup>3,6</sup>

RESTYLANE<sup>®</sup>  
LYFT<sup>™</sup>    RESTYLANE<sup>®</sup>  
DEFYNE<sup>™</sup>

11 CHIN<sup>3,6</sup>



RESTYLANE<sup>®</sup>  
LYFT<sup>™</sup>    RESTYLANE<sup>®</sup>  
DEFYNE<sup>™</sup>

12 NECK & DÉCOLLETAGE<sup>10,11</sup>

RESTYLANE<sup>®</sup>  
SKINBOOSTERS<sup>™</sup>

13 HANDS<sup>10,11</sup>

RESTYLANE<sup>®</sup>  
SKINBOOSTERS<sup>™</sup>





# THE WORLD'S MOST DIVERSE RANGE OF FILLERS AND SKINBOOSTERS

FOR BESPOKE, NATURAL-LOOKING RESULTS<sup>1-12,39</sup>

EACH AND EVERY PRODUCT IN OUR RANGE OF FILLERS AND SKINBOOSTERS IS **INDIVIDUALLY ENGINEERED** FOR A DIFFERENT PURPOSE, **SO THAT YOU CAN CREATE A LOOK TAILORED TO EACH PATIENT.**<sup>1,2,12,39</sup>

WITH DIFFERENT TECHNOLOGIES SUITED FOR EACH TREATMENT AREA, YOU CAN CRAFT TREATMENTS TO **LEAVE YOUR PATIENTS FILLED WITH CONFIDENCE.**<sup>12,39-41</sup>

1 SKIN QUALITY<sup>10,11</sup>

RESTYLANE<sup>®</sup> SKINBOOSTERS<sup>™</sup>

2 TEAR TROUGHS<sup>5</sup>

RESTYLANE<sup>®</sup>

3 TEMPLES<sup>7</sup>

RESTYLANE<sup>®</sup> VOLYME<sup>™</sup>

4 CHEEKS<sup>3,7</sup>

RESTYLANE<sup>®</sup> LYFT<sup>™</sup>

RESTYLANE<sup>®</sup> VOLYME<sup>™</sup>

5 NOSE<sup>3</sup>

RESTYLANE<sup>®</sup> LYFT<sup>™</sup>

6 NASOLABIAL FOLDS<sup>4,6,9</sup>

RESTYLANE<sup>®</sup>

RESTYLANE<sup>®</sup> DEFYNE<sup>™</sup>

RESTYLANE<sup>®</sup> REFYNE<sup>™</sup>

7 PERIORAL LINES<sup>9</sup>

RESTYLANE<sup>®</sup> REFYNE<sup>™</sup>

8 MARIONETTE LINES<sup>4,9</sup>

RESTYLANE<sup>®</sup>

RESTYLANE<sup>®</sup> REFYNE<sup>™</sup>

9 LIPS<sup>8</sup>

RESTYLANE<sup>®</sup> KY SSE<sup>™</sup>

10 JAWLINE<sup>3,6</sup>

RESTYLANE<sup>®</sup> LYFT<sup>™</sup>

RESTYLANE<sup>®</sup> DEFYNE<sup>™</sup>

11 CHIN<sup>3,6</sup>

RESTYLANE<sup>®</sup> LYFT<sup>™</sup>


RESTYLANE<sup>®</sup> DEFYNE<sup>™</sup>

12 NECK & DÉCOLLETAGE<sup>10,11</sup>

RESTYLANE<sup>®</sup> SKINBOOSTERS<sup>™</sup>

13 HANDS<sup>10,11</sup>

RESTYLANE<sup>®</sup> SKINBOOSTERS<sup>™</sup>





# TWO COMPLEMENTARY TECHNOLOGIES

GIVING YOU THE RANGE TO CREATE ANY AND EVERY LOOK<sup>3-11,13,39</sup>


THE COMPLEMENTARY NATURE OF THE RESTYLANE PORTFOLIO  
ALLOWS FOR:<sup>10,15,18</sup>

- INDIVIDUALIZED, NATURAL-LOOKING RESULTS
- LONG-LASTING IMPROVEMENT
- LONG-TERM SATISFACTION IN PATIENTS' SELF-CONFIDENCE

## NASHA<sup>®</sup> ENGINEERED FOR LIFTING AND PRECISION WITHOUT VOLUMIZATION<sup>1,13,39,42</sup>



The firmest gels available\* provide the right amount of **projection and support** where needed<sup>1,39</sup>




Targeted tissue integration with minimal distribution after injection allowing **precise and pronounced lifting capacity**\*\*†<sup>13,39,42</sup>



High performance, well suited for **lifting and structure without volumization**<sup>23,24,39</sup>

### NASHA IS THE ORIGINAL HYALURONIC ACID GEL TECHNOLOGY<sup>‡27</sup>

- The closest to natural HA gel technology on the market<sup>17</sup>
- Trusted by healthcare practitioners for over 25 years<sup>27</sup>




Adapted from Nikolis A et al. 2020.<sup>13</sup>

## OBT<sup>™</sup> ENGINEERED FOR CONTOURING AND NATURAL EXPRESSION<sup>13,20,39</sup>



Soft and flexible<sup>¶</sup> for tailored **contouring and volumization of dynamic areas** of the face<sup>1,19,20,39</sup>




Allow for **distributed product integration** that gives **vertical lift and horizontal volume**\*\*†<sup>13,19,42</sup>



The first HA fillers clinically proven to have positive effects on the **naturalness of dynamic facial expressions**<sup>20,25</sup>

### OBT GELS DEMONSTRATE FLEXIBILITY FROM ALL ANGLES<sup>1,25,43</sup>

- Resilience to dynamic movement
- Resistance to compression
- Ability to stretch



Adapted from Nikolis A et al. 2020.<sup>13</sup>

### FOR BOTH NASHA AND OBT TECHNOLOGIES:

BY CHOOSING THE TECHNOLOGY BEST SUITED FOR EACH PATIENT AND TREATMENT AREA<sup>13,41</sup>

Craft treatments that fill your patients with confidence<sup>13,41</sup>

>96%

felt treatment improved their appearance<sup>§41</sup>

100%

of patients found their results natural-looking<sup>§41</sup>

75%

MORE THAN 75% OF PATIENTS found they looked less tired and felt more attractive<sup>§41</sup>

\* G' is a measure of gel firmness (resistance to deformation), which can be used to understand how a gel's physical properties relate to its in vivo performance.  
 \*\* Product integration was assessed in an ex vivo human skin model using histological methods.<sup>42</sup>  
 † The firm gel structure of NASHA prevents distribution into the surrounding tissue after injection, enabling targeted product integration and precision.<sup>42</sup>  
 ‡ Restylane injectable gel was first approved for marketing and sale in September 1996 in the EU.<sup>27</sup>  
 § Of patients treated with either Restylane Volyme or Restylane Lyft.<sup>13</sup>  
 ¶ The flexibility of HA fillers can be accurately measured as xStrain.<sup>12</sup> Higher xStrain values correlate with increased gel flexibility.<sup>12</sup>  
 HA, hyaluronic acid; NASHA, Non-Animal Stabilized Hyaluronic Acid; OBT, Optimal Balance Technology.

# TWO TECHNOLOGIES WITH A RANGE OF GEL TEXTURES

FOR INDIVIDUALLY ENGINEERED PRODUCTS TO ACHIEVE A PRECISE LOOK<sup>3-13,39</sup>


THE RANGE TO **LIFT WITH PRECISION** AND **CREATE DYNAMIC FACIAL EXPRESSION** IN ALL SKIN TYPES AND TONES.<sup>3-11,23,28,29,39,44</sup>

- NASHA GELS: SPECIFIC AND CONSISTENT PARTICLE SIZE
- OBT GELS: CONSISTENT TEXTURE, PARTICLE SIZE AND SMOOTHNESS

## NASHA ENGINEERED FOR LIFTING AND PRECISION<sup>39,42</sup>

- The NASHA technology offers **gels with minimal modification**, for the **closest composition to natural HA**<sup>17,18,44</sup>
- The **unique particle size** of NASHA gels allow **tailored treatment** with the fillers **closest to natural HA**<sup>44</sup>

A patented crosslinking stabilization technique **preserves natural entanglements for stability and strength**<sup>17</sup>




**ENTANGLEMENT OF HA CHAINS (NATURAL CROSSLINKS)**

**SYNTHETIC CROSSLINKS**


Mesh filtering system creates a **specific and consistent gel size** for each NASHA-based product<sup>44</sup>

RESTYLANE®



**SMALLER PARTICLES** FOR TREATMENT OF FINER DETAIL IN WRINKLES AND FOLDS<sup>44</sup>

RESTYLANE®  
LYFT



**LARGER PARTICLES** FOR SEVERE WRINKLES AND GREATER LIFTING CAPACITY<sup>44</sup>

## OBT ENGINEERED FOR CONTOURING AND NATURAL EXPRESSION<sup>13,20,39</sup>

- The OBT technology offers gels that each have a **unique gel calibration and crosslinking profile**<sup>20,44,45</sup>
- The unique nature of OBT gels offer **flexible support for dynamic areas** of the face, **enabling naturalness of facial expression**<sup>20,44,45</sup>

**Different sizes of gel calibration and different degrees of crosslinking** create a **uniquely flexible gel** for each OBT-based product<sup>44,45</sup>

RESTYLANE®  
REFYNE™




SMALLER CALIBRATION  
MORE FLEXIBLE



RESTYLANE®  
KYSSE™




SMALLER CALIBRATION  
MEDIUM FLEXIBILITY



RESTYLANE®  
VOLYME™




LARGER CALIBRATION  
MEDIUM FLEXIBILITY



RESTYLANE®  
DEFYNE™




MEDIUM CALIBRATION  
LESS FLEXIBLE



# THE MOST DIVERSE RANGE OF INDIVIDUALLY ENGINEERED HA FILLERS ON THE MARKET<sup>1,3-9,12</sup>

THE RESTYLANE RANGE OFFERS YOU

- THE WORLD'S FIRMEST GEL FOR **STRUCTURE AND PROJECTION**<sup>1,3</sup>
- OUR MOST FLEXIBLE GEL FOR **DYNAMIC MOVEMENT AND EXPRESSION**<sup>1,9</sup>



\*G' is a measure of gel firmness (resistance to deformation), which can be used to understand how a gel's physical properties relate to its in vivo performance.<sup>12</sup>

\*\* xStrain is an index of gel flexibility (how much strain a gel can withstand and still be reversible).<sup>12</sup>

HA, hyaluronic acid.



Restylane

# THE RANGE FOR ANY AND EVERY LOOK

WITH THE **MOST DIVERSE RANGE** AVAILABLE, RESTYLANE  
GIVES YOU **UNPRECEDENTED CONTROL** FOR YOUR ARTISTRY<sup>1,3-9,39</sup>



**LYFT™**



## ULTIMATE PROJECTION

Offers the **highest projection and lift without volumizing**, providing strong definition with precision<sup>1,3</sup>

**RESTYLANE®**



## VERSATILE SUPPORT

A firm gel that **fills lines and wrinkles**, providing **versatile support**<sup>4</sup>

**DEFYNE™**



## SUBTLE DEFINITION

A moderately soft and flexible gel that offers **subtle definition and flexible support to enhance contour**<sup>6</sup>

**VOLYME™**



## EFFORTLESS VOLUME

A moderately soft gel with larger particle size for **volumizing with subtle projection, replacing volume loss, restoring natural contours and creating fullness**<sup>7</sup>

**KYSSE™**



## KISSABLE LIPS

A soft and flexible gel to **plump, soften and naturally enhance lips, restoring shape and improving texture**<sup>8</sup>

**REFYNE™**



## FLEXIBLE REFINEMENT

Offers smooth tissue integration and the **most flexible support for softening and filling fine lines**<sup>9</sup>

FIRM

FLEXIBLE

# RESTYLANE<sup>®</sup> LYFT<sup>™</sup> ULTIMATE PROJECTION

RESTYLANE LYFT IS DESIGNED TO DELIVER PROJECTION AND STRUCTURE FOR A **PRONOUNCED EFFECT AND OPTIMAL LIFTING WITHOUT VOLUMIZING**<sup>3,13,39</sup>

## HIGHEST G' IN THE MARKET\*1

- Firm gel texture and controlled particle size for **greater projection**<sup>1,12</sup>

## FOR OPTIMAL LIFT AND PROJECTION WITHOUT VOLUMIZING<sup>16,39,42</sup>

- Resists dynamic forces<sup>6</sup>

## LOW DISTRIBUTION AND INTEGRATION INTO SURROUNDING TISSUE<sup>42</sup>

- Targeted placement delivers **precise results**<sup>42</sup>

## PROJECTION AND STRUCTURE<sup>16,39</sup>

- For a pronounced effect<sup>16,39</sup>

## AREAS TO USE<sup>3</sup>



CHEEKS

NOSE

JAWLINE

CHIN



## DURATION\*\*23



of sustained **aesthetic improvement**<sup>23</sup>

## PATIENT SATISFACTION:



99%

of patients **would recommend the treatment to a friend**<sup>32</sup>

96%

of patients felt their treatment **met or exceeded expectations**<sup>32</sup>

## THE TREATMENT RESULTS ARE NATURAL LOOKING<sup>41</sup>



100%

of patients said that **results were natural looking** at both **4 and 8 weeks** post-treatment<sup>41</sup>



## WELL-ESTABLISHED SAFETY PROFILE<sup>36,38</sup>

MORE THAN 20 CLINICAL STUDIES ENCOMPASSING **OVER 1,500 PATIENTS**<sup>36</sup>

- Compared with Juvéderm<sup>®</sup> Volbella<sup>®</sup>, currently approved Restylane NASHA fillers - including Restylane Lyft - have been associated with a **lower incidence of nodule formation and inflammatory events**<sup>†38</sup>
- Patients treated with Restylane Lyft had numerically **fewer adverse events** than patients treated with Teosyal<sup>®</sup> RHA 4<sup>46</sup>

RESTYLANE LYFT: DESIGNED TO **LIFT AND PROJECT**, FOR **STRUCTURE WITHOUT VOLUME**<sup>3,13,39</sup>



\* G' is a measure of gel firmness (resistance to deformation), which can be used to understand how a gel's physical properties relate to its in vivo performance<sup>12</sup>  
 \*\* At 24 months 93% of patients (N=100) had self-evaluated improvements and 82% had physician-assessed improvements following one retreatment.<sup>23</sup>  
 † In a retrospective chart review, the incidence of delayed nodules in all patients who had received Juvéderm<sup>®</sup> Vycross<sup>®</sup> fillers during a 12-month period was assessed (1250 treatments in 1029 patients).<sup>38</sup> Compared with the FDA summary of safety and effectiveness data for NASHA<sup>®</sup> fillers, Juvéderm<sup>®</sup> Volbella<sup>®</sup> was associated with a higher incidence of nodule formation.<sup>38</sup>

GAIS, Global Aesthetic Improvement Scale; GCRS, Global Chin Retrusion Scale; NASHA<sup>®</sup>, Non-Animal Stabilized Hyaluronic Acid; NLF, nasolabial fold.



# RESTYLANE<sup>®</sup> KY SSE<sup>™</sup> KISSABLE LIPS

RESTYLANE<sup>®</sup> KY SSE<sup>™</sup> IS PURPOSEFULLY DESIGNED FOR SOFT, PLUMP, AND NATURAL-LOOKING LIPS<sup>1,8,47,48</sup>

## THE IDEAL BALANCE OF FLEXIBILITY AND SUPPORT<sup>1,12,48</sup>


- As an OBT gel, the high xStrain of **Restylane Kysse facilitates movement**<sup>\*1,12</sup>
- The **soft, flexible gel texture** distributes more evenly to provide **natural-looking enhancement** for even **more kissable lips**<sup>42,47,48</sup>

## WELL-ESTABLISHED SAFETY PROFILE<sup>21,34,48</sup>

- Restylane Kysse has a **favorable safety profile** based on clinical experience<sup>21,34,48</sup>
- For treatment of the lips, Restylane Kysse has demonstrated **minimal swelling** vs. Juvéderm<sup>®</sup> products<sup>21</sup>

## ACHIEVE OPTIMAL PERFORMANCE AND LONG-LASTING OUTCOMES WITH LESS<sup>21</sup>

- Restylane Kysse achieved **durable results** in the lips, **lasting up to 12 months**<sup>\*\*21</sup>
- Restylane Kysse achieved enhanced volume with **significantly less (-20%) product** than Juvéderm<sup>®</sup> Volbella<sup>®†121,34</sup>



Adapted from Weiss R et al. 2021.<sup>34</sup>

## AREAS TO USE<sup>8</sup>



LIPS



## DURATION<sup>21</sup>



of **soft, plump, and natural-looking lips**<sup>21</sup>

RESTYLANE KY SSE OFFERS UNBEATABLE SATISFACTION FOR PATIENTS AND THEIR PARTNERS<sup>21,47,48</sup>

## PATIENT SATISFACTION:



**100%**

of patients reported **aesthetic improvement** after treatment<sup>48</sup>

**100%**

of patients were **satisfied or very satisfied** with the lip style after treatment<sup>§21,47</sup>


**>98%**

of patients were **satisfied with the kissability of their lips** after treatment<sup>¶47</sup>


**96%**

of patients agreed that their **lips looked natural**<sup>47</sup>


## PARTNER SATISFACTION:



partners **liked the way** their partner's lips looked and felt<sup>#47</sup>



of partners agreed their partner's lips had a **more kissable and natural feel**<sup>††47</sup>



\* xStrain is an index of gel flexibility (how much strain a gel can withstand and still be reversible).<sup>12</sup>  
 \*\* Optional retreatment was offered at 12 months and a maximum total volume of 3 ml was permitted.<sup>21</sup> Touch-up was allowed after 2 weeks.<sup>21</sup>  
 † In a 12-month, randomized clinical study, 60 patients received Restylane Kysse (n=31) or Juvéderm<sup>®</sup> Volbella<sup>®</sup> (n=29) to treat the lips.<sup>21</sup> The total volumes injected at initial treatment and touch-up, and the volumes injected at optional retreatment were reported.<sup>21</sup> A smaller total volume of study product was required in the Restylane Kysse group than in the Juvéderm<sup>®</sup> Volbella<sup>®</sup> group (1.54 ml vs. 1.94 ml in both lips together; P<0.001) to achieve optimal correction of lip fullness.<sup>21</sup>  
 ‡ In a 40-week, randomized, controlled, evaluator-blinded study, 270 patients received Restylane Kysse (n=183) or Juvéderm<sup>®</sup> Volbella<sup>®</sup> (n=87) to treat the lips and perioral area.<sup>34</sup> The mean volume injected in the lips was 1.82 ml (Restylane Kysse) and 2.24 ml (Juvéderm<sup>®</sup> Volbella<sup>®</sup>); P<0.001.<sup>34</sup>  
 § As assessed by patients and investigators for both upper and lower lips (lips rated as "improved", "much improved", or "very much improved") (N=31).<sup>21</sup>  
 ¶ As assessed by subject satisfaction questionnaires 8 weeks after treatment, N=59.<sup>47</sup>  
 † As assessed by patients in the Galderma KISSABILITY Questionnaire ("very satisfied", "satisfied" vs. "neutral", "unsatisfied", "very unsatisfied", N=59.<sup>47</sup>  
 # Partners who rated "very satisfied", "satisfied" vs. "neutral", "unsatisfied" or "very unsatisfied", N=59.<sup>47</sup>  
 †† As assessed by partners in the Galderma KISSABILITY Questionnaire, N=59.<sup>47</sup>  
**OBT**, Optimal Balance Technology.

# RESTYLANE® VOLYME™ EFFORTLESS VOLUME

RESTYLANE® VOLYME™ IS SPECIFICALLY DESIGNED TO RESTORE THE NATURAL CONTOURS OF THE MIDFACE FOR A YOUTHFUL LOOK<sup>7,13,19,22,39,49</sup>

## A GEL FORMULATION THAT DELIVERS NATURAL-LOOKING VOLUME<sup>13,19,22,45,49,50</sup>


- A **soft and moderately flexible gel** specifically designed to **restore the natural contours of the midface** for a youthful look<sup>13,19,22,39,49</sup>
- **Integrates with the tissue** and allows patients to **move naturally with a joyful expression**<sup>13,42</sup>

## DEMONSTRATED CLINICAL EFFICACY WORLDWIDE FOR OVER 10 YEARS\*<sup>51</sup>

- Volumizing effects were maintained for **up to 18 months**<sup>19</sup>
- **Achieve durable results** and **strong volumizing effects** in the midface, lasting **up to 18 months**<sup>19</sup>

## ACHIEVE OPTIMAL AESTHETIC OUTCOMES WITH LESS<sup>22</sup>

- **Significantly less Restylane Volyme was needed** to show an improvement in midface fullness results vs. Juvéderm® Voluma™, 12 weeks after treatment<sup>22</sup>
- Restylane Volyme required **significantly less (13%) product** vs. Juvéderm® Voluma™ — 4.3 ml vs. 4.9 ml, respectively (P=0.0134)\*\*<sup>22</sup>



Adapted from Jones D et al. 2021.<sup>22</sup>

### AREAS TO USE<sup>7</sup>



TEMPLE

CHEEKS



### DURATION<sup>19</sup>



of durable results and strong **volumizing effects in the midface**<sup>19</sup>

### PATIENT SATISFACTION:



100% 100%

of patients **would recommend** the treatment<sup>†19</sup>

of patients **would receive the treatment again**<sup>†19</sup>

### THE TREATMENT IMPROVED MY APPEARANCE:



At 4 weeks

93%

At 8 weeks

>97%

of patients felt that the treatment **improved their appearance**<sup>†41</sup>



### WELL-ESTABLISHED SAFETY PROFILE<sup>13,19,22,49,51,52</sup>

RESTYLANE VOLYME IS WELL TOLERATED WITH A SAFETY PROFILE BUILT ON **OVER 10 YEARS OF CLINICAL DATA**<sup>\*13,19,22,49,51,52</sup>

RESTYLANE VOLYME: DESIGNED TO ADD **NATURAL-LOOKING VOLUME** AND **CREATE FULLNESS**<sup>13,19,22,39,49</sup>



\* Restylane Volyme was approved for marketing and sale in the EU in 2010.<sup>51</sup>  
 \*\* The mean total volumes injected at initial treatment and touch-up were reported. Patients treated with Restylane Volyme (n=142) required less total mean volume injected to achieve optimal aesthetic results compared with Juvéderm® Voluma™ (n=68). Touch-up was allowed at 4 weeks.<sup>22</sup>  
 † As assessed by subject satisfaction questionnaires. Patients who reported that they were "satisfied" or "very satisfied". N=60.  
 GAIS, Global Aesthetic Improvement Scale; GCRS, Global Chin Retrusion Scale; NLF, nasolabial fold.




# EXPERTS IN FACIAL DYNAMICS

THE **FIRST HA FILLERS** CLINICALLY PROVEN TO HAVE POSITIVE EFFECTS ON THE **NATURALNESS OF DYNAMIC FACIAL EXPRESSIONS**<sup>25,53,54</sup>

RESTYLANE DEFYNE AND RESTYLANE REFYNE ARE **THE FIRST HA FILLERS** THAT DEMONSTRATE EXPERTISE IN REDUCING FACIAL STRAIN AND **RESTORING YOUTHFUL STRAIN DYNAMICS IN VIVO**<sup>25</sup>

**OLDER INDIVIDUALS DISPLAY HIGHER AMOUNTS OF FACIAL STRAIN DURING DYNAMIC EXPRESSION THAN YOUNGER INDIVIDUALS**<sup>25</sup>

- Restylane Defyne is clinically proven to help **restore youthful dynamic strain profiles**<sup>\*25</sup>
- Following treatment with Restylane Defyne dynamic 3D video imaging demonstrated a reduction in the amount of strain exerted<sup>\*\*,+25</sup>



Objective facial dynamic results (3D stereophotogrammetry) at baseline and after treatment with Restylane Defyne<sup>25</sup>

PATIENT SATISFACTION:



97%

of patients **were satisfied** with their treatment, 1 month after treatment<sup>‡20</sup>

95%

of patients **would recommend** the treatment to a friend, 1 month after treatment<sup>‡55</sup>

## RESTYLANE<sup>®</sup> DEFYNE<sup>™</sup> SUBTLE DEFINITION




AREAS TO USE<sup>6</sup>



NASOLABIAL FOLDS

MENTAL CREASE

CHIN



**A MODERATELY SOFT AND FLEXIBLE GEL DESIGNED TO PROVIDE CONTOURING & DEFINITION**<sup>6,12,25,39,50,54</sup>

- Provides **flexible support** for nasolabial folds and chin **with dynamic movement**<sup>1,6,12,56,57</sup>
- Durable results that last **up to 12 months**<sup>56</sup>

## RESTYLANE<sup>®</sup> REFYNE<sup>™</sup> FLEXIBLE REFINEMENT



AREAS TO USE<sup>9</sup>



PERIORAL LINES

NASOLABIAL FOLDS

MARIONETTE LINES



**A SMOOTH FLEXIBLE GEL DESIGNED TO FILL LINES AND WRINKLES**<sup>1,9,12,58</sup>

- Provides the **most flexible support and smooth tissue integration** for marionette lines, perioral lines, and nasolabial folds<sup>1,54</sup>
- Sustained improvement in wrinkle severity **up to 12 months**<sup>§53</sup>



**WELL-ESTABLISHED SAFETY PROFILE**<sup>||52</sup>

THE SAFETY PROFILE OF RESTYLANE DEFYNE AND RESTYLANE REFYNE HAS BEEN ESTABLISHED IN OVER 10 CLINICAL INVESTIGATIONS ENCOMPASSING **MORE THAN 1000 PATIENTS**<sup>52</sup>

RESTYLANE DEFYNE AND RESTYLANE REFYNE: DESIGNED TO **WORK TOGETHER TO RESTORE THE YOUTHFUL DYNAMIC FACIAL EXPRESSION** YOUR PATIENTS WANT<sup>25</sup>

<sup>\*</sup> Dynamic strain is the degree of stretch and compression of the skin surface from neutral to maximum facial expression.<sup>25</sup>  
<sup>\*\*</sup> In a study analyzing quantitative dynamic strain, 30 female patients (aged 41-65 years) with moderate-to-severe bilateral NLFs and marionette lines received Restylane Refyne, Restylane Defyne, or both, and were compared with a "younger" untreated group (n=20; aged 25-35 years).<sup>25,54</sup>  
<sup>†</sup> The degree of facial strain was assessed by 3D digital stereophotogrammetry at baseline and 42 days after treatment.<sup>25</sup>  
<sup>‡</sup> Pooled results for both Restylane Refyne and Restylane Defyne. As assessed by subject and investigator satisfaction questionnaires. N=total sample number.<sup>20,53</sup>  
<sup>§</sup> Touch-up was allowed at 2 weeks after initial treatment.<sup>53</sup>  
<sup>||</sup> 10r equivalent product without lidocaine.<sup>52</sup>  
**HA**, hyaluronic acid; **NLF**, nasolabial fold.

# RESTYLANE® DEFYNE™ CHIN ENHANCEMENT LASTING UP TO 12 MONTHS<sup>57</sup>

RESTYLANE DEFYNE HAS AN IDEAL BALANCE OF **FIRMNESS AND FLEXIBILITY** FOR **CONTOURING** AND **DEFINING THE CHIN**.<sup>\*1,6,12</sup>

- Firmness to provide the support needed to **enhance chin projection**<sup>1,12,50</sup>
- Flexibility to maintain **natural expression and movement**<sup>1,12,50</sup>


## YOUR PATIENTS SEE THEMSELVES HEAD ON

- That's why many may not notice mild to moderate chin retrusion
- Even if they do, they may not be familiar with the option of a chin filler<sup>59</sup>

## HELP YOUR PATIENTS SEE CHIN RETRUSION

- 1 Have your patient mimic a Ricketts E-line by drawing a line down from their lower lip
- 2 Explain that the ideal chin should only be a few millimeters below that line
- 3 Help patients understand that correcting chin retrusion improves their overall facial proportions

## SEE CHIN RETRUSION



No retrusion

Mild retrusion

Moderate retrusion

Substantial retrusion

## DURATION<sup>57</sup>



of **aesthetic improvement** in the chin<sup>57</sup>

## INJECTOR SATISFACTION:



100%

said Restylane Defyne **improved the appearance of patients' chin projection** at 12 weeks<sup>\*\*57</sup>

96%

still agreed at 1 year<sup>\*\*57</sup>

## THE TREATMENT IMPROVED MY APPEARANCE



12 weeks after treatment with Restylane® Defyne™ to address the chin area:

>99%

of patients said the appearance of their **chin had improved**<sup>†57</sup>

100%

of patients were reported to **have improved**<sup>†57</sup>



## RESTYLANE® DEFYNE™ HAS A PROVEN SAFETY PROFILE FOR CHIN DEFINITION<sup>57</sup>

- Most patients (86%) did not experience any adverse events related to treatment<sup>57</sup>
  - Of those events, **23/24 were mild** in severity, and there were **no serious adverse events**<sup>57</sup>
- The most commonly observed side effects include pain, bruising, and swelling at the injection site<sup>57</sup>

RESTYLANE® DEFYNE™: DESIGNED TO PROVIDE LASTING **PROJECTION AND NATURAL MOVEMENT FOR THE CHIN**<sup>1,6, 12,50,57</sup>



<sup>\*</sup> HA-based filler products have been tested for firmness (G') and flexibility (xStrain) using rheometry. G' value reflects the gel firmness (support) of a product. xStrain is an index of gel flexibility (how much strain a gel can withstand and still be reversible).<sup>12</sup>  
<sup>\*\*</sup> GAIS rating of "improved," "much improved," and "very much improved." Touch-up was allowed at 4 weeks after initial treatment. Optional re-treatment with Restylane Defyne was permitted at 48 weeks after initial treatment.<sup>57</sup>  
<sup>†</sup> As assessed by patients and treating investigators on the 7-point GAIS (patients who were scored as "improved" "much improved" or "very much improved"). N=107.<sup>57</sup>  
**GAIS**, Global Aesthetic Improvement Scale; **HA**, hyaluronic acid.



# RESTYLANE® VERSATILE SUPPORT

RESTYLANE IS A FIRM GEL DESIGNED TO DELIVER **VERSATILE FILLING AND PROJECTION** WHERE YOUR PATIENTS NEED IT<sup>1,4,12,60</sup>

## HERITAGE BUILT ON MORE THAN TWO DECADES OF REAL-WORLD EXPERIENCE<sup>26,27</sup>

- The **original** hyaluronic acid (HA) filler\*<sup>27</sup>
- **Minimally modified** for a composition close to natural HA<sup>17,18</sup>

## DURABLE RESULTS THAT ARE SUSTAINED FOR UP TO 36 MONTHS\*\*<sup>24</sup>

## HIGH PATIENT SATISFACTION FOR UP TO 36 MONTHS WITH ONE RETREATMENT<sup>23,24</sup>

- **>96%** of patients felt that they **would do the treatment again**<sup>†23</sup>

## WELL-ESTABLISHED AND FAVORABLE SAFETY PROFILE<sup>26,27,29,61</sup>

- Compared with Juvéderm® Volbella®, currently approved Restylane NASHA fillers (including Restylane) have been associated with a **lower incidence of nodule formation and inflammatory events**<sup>‡38</sup>

# 100%

of patients reported **improvements at 14 days after treatment**<sup>§62</sup>



of **sustained aesthetic improvement**<sup>24</sup>


## AREAS TO USE<sup>4</sup>



INFRAORBITAL HOLLOW

NASOLABIAL FOLDS

MARIONETTE LINES



RESTYLANE: THE **ORIGINAL** DESIGNED FOR **LONG-LASTING EFFECT**<sup>24,27</sup>



\* Restylane injectable gel was first approved for marketing and sale in September 1996 in the EU.<sup>27</sup>

\*\* With one retreatment.<sup>24</sup>

† As measured by subject satisfaction questionnaires regarding treatment conducted at timepoints throughout the study (N=100).<sup>23</sup>

‡ In a retrospective chart review, the incidence of delayed nodules in all patients who had received Juvéderm® Vycross® fillers during a 12-month period was assessed (1250 treatments in 1029 patients).<sup>38</sup> Compared with the FDA summary of safety and effectiveness data for NASHA fillers, Juvéderm® Volbella® was associated with a higher incidence of nodule formation.<sup>38</sup>

§ As evaluated by subject-rated improvement in the GAIS (ratings: "very much improved", "much improved", "improved" vs "no change", "worse") (N=60).<sup>62</sup>


EU, European Union; FDA, Food and Drug Administration; GAIS, Global Aesthetic Improvement Scale; NASHA, Non-Animal Stabilized Hyaluronic Acid.

# RESTYLANE® SKINBOOSTERS™

THE ONLY SKIN-BOOSTING INJECTABLE CLINICALLY PROVEN TO ENHANCE 6 KEY ASPECTS OF SKIN QUALITY<sup>10,11,63-69</sup>

THE ORIGINAL AND LONG-LASTING SKIN CARE INJECTABLE WITH INSTANT DEEP HYDRATION AND IMMEDIATE RESULTS THAT LAST FOR UP TO 15 MONTHS<sup>\*10,11,63,69</sup>

UNMATCHED PERFORMANCE  
CLINICALLY PROVEN TO ENHANCE 6 KEY ASPECTS  
OF SKIN QUALITY<sup>63-69</sup>



RESTYLANE SKINBOOSTERS IS **THE MOST VERSATILE SKIN-BOOSTING TREATMENT AVAILABLE**\*\*†<sup>28,63-70</sup>

- FOR **EVERY SKIN TYPE AND TONE**
- OFFERING **SMOOTH, EVEN, YOUNGER-LOOKING, AND GLOWING SKIN** ACROSS DIFFERENT TREATMENT AREAS



**CLINICALLY PROVEN TO BOOST SKIN QUALITY FOR SMOOTH, EVEN, YOUNGER-LOOKING, AND GLOWING SKIN**<sup>63-69</sup>

Patients with dry, dull, uneven, crêpey skin can benefit from treatment with Restylane Skinboosters to boost their overall skin quality<sup>63-69</sup>



**FAST-ACTING, IMMEDIATE, DEEP AND LONG-LASTING HYDRATION**<sup>63,69</sup>

Restylane Skinboosters uses the natural ability of HA to bind water molecules, locking moisture within the skin<sup>10,11, 63,69</sup>



**LONGEST LASTING WITH UNMATCHED EFFECT FOR UP TO 15 MONTHS**<sup>63,71,72</sup>

Restylane Skinboosters offers the longest duration of skin quality improvements across HA injectables available on the market<sup>63,71,72</sup>



**MOST TRUSTED WITH WELL-ESTABLISHED SAFETY PROFILE FOR OVER 18 YEARS**<sup>163-68,73</sup>

Restylane Skinboosters has a clinical safety profile built on over 18 years of clinical use and experience<sup>163-68,73</sup>



**THE CLOSEST TO NATURAL STABILIZED HA TO IMPROVE THE NATURAL SKIN STRUCTURE AND SKIN HYDRO-BALANCE**<sup>3-6,15,16</sup>

Based on NASHA crosslinking technology improving both skin structure and hydro-balance<sup>17,63-66,74</sup>



**FREQUENTLY RECOMMENDED AND WITH CONSISTENTLY HIGH PATIENT SATISFACTION**<sup>28,65,74</sup>

Following their experience and results with Restylane Skinboosters, most patients want to repeat and continue their treatment<sup>28,65,74</sup>

FACE (CHEEKS, CHIN, PERIORAL, FOREHEAD, TEMPLES)<sup>10,11</sup>

NECK<sup>10,11</sup>

DÉCOLLETAGE<sup>10,11</sup>



HANDS<sup>10,11</sup>

\* In a 15-month randomized, multi-center, evaluator-blinded, split-hand, no treatment-controlled study, 100 Chinese patients received treatment with Restylane Skinboosters Vital to treat one dorsal hand.<sup>3</sup> During the study period, three treatments were administered in the same hand starting with initial treatment and then spaced 1 month apart.<sup>63</sup>

\*\* Suitable for patients aged 18 years and older.<sup>70</sup>

† Skin types refers to the Fitzpatrick scale (also Fitzpatrick skin typing test; or Fitzpatrick phototyping scale), a numerical classification schema for human skin color.<sup>29</sup> This includes six categories, covering all the range of skin colors from palest (Type I) to darkest (Type VI).<sup>29</sup>

‡ Restylane Skinboosters Vital obtained first CE certification in Europe in 2004.<sup>75</sup>

CE, Conformité Européenne; HA, hyaluronic acid; NASHA, Non-Animal Stabilized Hyaluronic Acid.



# RESTYLANE SKINBOOSTERS

GIVE YOUR PATIENTS A **LASTING BOOST IN CONFIDENCE AND SELF-ESTEEM** THAT LEAVES THEM **GLOWING FROM WITHIN**\*,\*\*40,66

**IDEAL FOR MANY SKIN TYPES, SKIN TONES, AND DIFFERENT TREATMENT AREAS**<sup>10,11,28,63,70</sup>

**RESTYLANE SKINBOOSTERS** OFFERS THE **MOST VERSATILE TREATMENT** OPTION WITH A COLLECTION OF TWO PRODUCTS BASED ON DIFFERENT HA CONCENTRATIONS DESIGNED TO **OPTIMALLY IMPROVE THE QUALITY OF MANY SKIN TYPES AND TONES IN ANY TREATMENT AREA**<sup>10,11,28,63,70</sup>




### RESTYLANE SKINBOOSTERS VITAL<sup>10,70</sup>

Ideal for patients and treatment areas with **regular to thicker skin** e.g., the midface, cheeks, forehead, temples, hands, and décolletage

### RESTYLANE SKINBOOSTERS VITAL LIGHT<sup>11,70</sup>

Ideal for patients and treatment areas with **thinner, more delicate skin** e.g., the perioral, periorcular areas or neck



### THE AWARD-WINNING BESPOKE SMARTCLICK™ SYRINGE SYSTEM<sup>10,11,75,76</sup>

The SmartClick syringe system uses an innovative and unique **audible dosage indicator** that increases safe use of Restylane Skinboosters<sup>10,11,75,76</sup>

**CAN BE USED AS STAND-ALONE TREATMENT OR IN COMBINATION WITH RESTYLANE FILLERS**<sup>70</sup>

### HIGH PATIENT SATISFACTION AND TREATMENT RECOMMENDATION<sup>65</sup>



12 months after initial treatment with Restylane Skinboosters:

91%

of patients (N=22) said they **wanted to repeat their treatment**<sup>65</sup>

96%

of patients would **recommend it to their friends**<sup>65</sup>

### THE LONGEST LASTING SKIN-BOOSTING INJECTABLE WITH RESULTS LASTING UP TO:

15<sup>x</sup>

longer than Prohilo<sup>®63,72</sup>

>1.5<sup>x</sup>

longer than Juvéderm<sup>®</sup> Volite<sup>®63,71</sup>

LIKE MANY BEAUTY CARE ROUTINES, IT IS **RECOMMENDED TO REPEAT TREATMENT EVERY 6-12 MONTHS** TO MAINTAIN A CONSISTENT IMPROVEMENT<sup>10,11</sup>

BEFORE



AFTER



\* As evaluated by self-assessment questionnaires.<sup>65</sup>

\*\* Patients received three treatment sessions: at baseline, Month 1 and Month 2.<sup>66</sup>

# ACHIEVE THE LOOK YOUR PATIENTS WANT<sup>3-9</sup>

PRODUCTS IN THE RESTYLANE RANGE **CAN BE USED  
IN COMBINATION** TO ACHIEVE ANY AND EVERY LOOK.<sup>3-9</sup>

KYLE, 28 YEARS<sup>3,5,7</sup>

BEFORE



AFTER



RESTYLANE®  
VOLYME™

**TEMPLES**  
1 ml/side

RESTYLANE®

**TEAR TROUGH**  
0.5 ml/side

RESTYLANE®  
LYFT™


**NASOLABIAL FOLDS**  
0.5 ml/side

ANAHITA, 35 YEARS<sup>3,8</sup>

BEFORE



AFTER



RESTYLANE®  
LYFT™

**CHIN**  
1 ml

**NOSE**  
1 ml

**CHEEKS**  
2 ml/side

RESTYLANE®  
KYSSE™

**LIP VOLUME**  
0.8 ml

YU, 39 YEARS<sup>3,5,6</sup>

BEFORE



AFTER



RESTYLANE®

**TEAR TROUGH**  
0.6 ml right, 0.5 ml left

RESTYLANE®  
LYFT™

**NOSE**  
0.5 ml

**NASOLABIAL FOLDS**  
0.5 ml center

RESTYLANE®  
DEFYNE™

**NASOLABIAL FOLDS**  
0.5 ml right

BONGI, 37 YEARS<sup>3,5</sup>

BEFORE



AFTER



RESTYLANE®  
LYFT™

**CHIN**  
1.5 ml

**JAWLINE**  
0.6 ml/side

**CHEEKS**  
0.4 ml/side

RESTYLANE®

**TEAR TROUGH**  
0.2 ml/side





# NASHA

# OBT

	 <b>LYFT</b>	 <b>RESTYLANE</b>	 <b>SKINBOOSTERS</b>	 <b>DEFYNE</b>	 <b>VOLYME</b>	 <b>KYSSE</b>	 <b>REFYNE</b>
KEY MESSAGES	<b>ULTIMATE PROJECTION<sup>39</sup></b> <ul style="list-style-type: none"> <li>Lift without volumizing</li> <li>Strong definition</li> </ul>	<b>VERSATILE SUPPORT<sup>4</sup></b> <ul style="list-style-type: none"> <li>Fills lines and wrinkles</li> <li>Versatile support</li> </ul>	<b>RADIANT SKIN<sup>10,11</sup></b> <ul style="list-style-type: none"> <li>Improve / enhance skin quality</li> <li>Restores skin structure, elasticity</li> <li>Delivers deep hydration</li> <li>Boosts radiance and glow</li> </ul>	<b>SUBTLE DEFINITION<sup>39</sup></b> <ul style="list-style-type: none"> <li>Flexible support</li> <li>Enhanced contour</li> </ul>	<b>EFFORTLESS VOLUME<sup>39</sup></b> <ul style="list-style-type: none"> <li>Volume with subtle projection</li> <li>Replacing volume loss</li> <li>Restoring natural contours and creating fullness</li> </ul>	<b>KISSABLE LIPS<sup>8</sup></b> <ul style="list-style-type: none"> <li>Plumps, softens and naturally enhances lips</li> <li>Restores shape and improves texture</li> </ul>	<b>FLEXIBLE REFINEMENT<sup>1,9</sup></b> <ul style="list-style-type: none"> <li>The most flexible support</li> <li>Smooth tissue integration</li> <li>Softens and fills fine lines</li> </ul>
GEL TEXTURE <sup>9,10</sup>	<b>HIGHLY FIRM</b> 	<b>FIRM GEL</b> 	<b>SOFT GEL</b> 	<b>MODERATELY FLEXIBLE</b> 	<b>FLEXIBLE</b> 	<b>FLEXIBLE</b> 	<b>HIGHLY FLEXIBLE</b> 
VOLUMIZING CAPACITY <sup>11</sup>	<b>HIGH</b>	<b>MODERATE</b>	<b>VERY LOW</b>	<b>HIGH</b>	<b>VERY HIGH</b>	<b>LOW</b>	<b>LOW</b>
LIFTING CAPACITY <sup>11</sup>	<b>VERY HIGH</b>	<b>VERY HIGH</b>	<b>LOW</b>	<b>HIGH</b>	<b>MODERATE / HIGH</b>	<b>LOW / MODERATE</b>	<b>LOW</b>
TREATMENT AREAS	<ul style="list-style-type: none"> <li>Cheeks</li> <li>Nose</li> <li>Chin</li> <li>Jawline<sup>3</sup></li> </ul>	<ul style="list-style-type: none"> <li>Undereye hollows</li> <li>NLF</li> <li>Marionette lines<sup>4</sup></li> </ul>	<ul style="list-style-type: none"> <li>Face</li> <li>Neck</li> <li>Décolletage</li> <li>Hands<sup>10,11</sup></li> </ul>	<ul style="list-style-type: none"> <li>NLF</li> <li>Chin, mental crease<sup>6</sup></li> </ul>	<ul style="list-style-type: none"> <li>Cheeks</li> <li>Temples<sup>7</sup></li> </ul>	<ul style="list-style-type: none"> <li>Lips<sup>8</sup></li> </ul>	<ul style="list-style-type: none"> <li>NLF</li> <li>Marionette lines</li> <li>Perioral lines<sup>9</sup></li> </ul>
NEEDLE RECOMMENDATION	27G (TWN) <sup>3</sup>	29G-30G (TWN) <sup>4</sup>	29G (TWN) <sup>10,11</sup>	27G x 1/2" (UTWN) <sup>6</sup>	27G x 1/2" (UTWN) <sup>7</sup>	30G x 1/2" (UTWN) <sup>8</sup>	30G x 1/2" (UTWN) <sup>9</sup>
CANNULA RECOMMENDATION	23G-25G <sup>3</sup>	27G-28G <sup>4</sup>	30G <sup>10,11</sup>	27G <sup>6</sup>	27G or wider <sup>7</sup>	25G-27G <sup>8</sup>	27G <sup>9</sup>
INJECTION DEPTH	 Deep dermis or subcutaneously <sup>3</sup>	 Mid-dermis <sup>4</sup>	 Mid to deep dermis <sup>10,11</sup>	 Deep dermis or subcutaneously <sup>6</sup>	 Supraperiosteally or subcutaneously <sup>7</sup>	 Vermillion lip, submucosal tissue <sup>8</sup>	 Mid-dermis <sup>9</sup>

TWN, thin-wall needle; UTWN, ultra-thin-wall needle.

# Shaping your aesthetic experience together

**GALDERMA**  
EST 1981  
**PREMIUM BRANDS**

**GALDERMA**  
EST 1981  
**PREMIUM services**


**GALDERMA AESTHETIC COLLECTION**

**SO MUCH TO GAIN**

	ANTI-AGING	INDIVIDUALIZED BEAUTY	SKIN QUALITY	
HA DERMAL FILLER	<i>Restylane</i>	<i>Restylane</i>		PRODUCT DATA
SKINBOOSTERS			<i>Restylane</i> SKINBOOSTERS™	CLINICAL SUPPORT
SKIN CARE			 PRESCRIPTION ACNE TREATMENT	BUSINESS SUPPORT
				<p><b>GAINCONNECT</b></p> <hr/> <p>HCP PORTAL Your needs at your fingertips</p>

**AART™**

Turn your AART™ into a HIT™. Translate your patients' insights into a treatment plan prioritizing the right selection of complementary Galderma products.





# REFERENCES

1. Galderma. Data on File. MA-43049.
2. Galderma. Data on File. MA-34483.
3. Restylane® Lyft™ EU IFU.
4. Restylane® EU IFU.
5. Restylane® Eyelight™ EU IFU.
6. Restylane® Defyne™ EU IFU.
7. Restylane® Volyme™ EU IFU.
8. Restylane® Kysse™ EU IFU.
9. Restylane® Refyne™ EU IFU.
10. Restylane® Skinboosters™ VITAL EU IFU.
11. Restylane® Skinboosters™ VITAL LIGHT EU IFU.
12. Öhrlund, Å., 2018. Evaluation of rheometry amplitude sweep cross-over point as an index of flexibility for HA fillers. *Journal of Cosmetics, Dermatological Sciences and Applications*, 8(02), p.47.
13. Nikolis, A., Enright, K.M., Lazarova, D. and Sampalis, J., 2020, January. The Role of Clinical Examination in Midface Volume Correction Using Hyaluronic Acid Fillers: Should Patients Be Stratified by Skin Thickness?. In *Aesthetic Surgery Journal Open Forum* (Vol. 2, No. 1, p. ojaa005). US: Oxford University Press.
14. Galderma. Data on File. MA-43039.
15. Galderma. Data on File. MA-34883.
16. Weiss, R.A., Moradi, A., Bank, D., Few, J., Joseph, J., Dover, J., Lin, X., Nogueira, A. and Mashburn, J., 2016. Effectiveness and safety of large gel particle hyaluronic acid with lidocaine for correction of midface volume deficit or contour deficiency. *Dermatologic Surgery*, 42(6), pp.699-709.
17. Edsman, K., Nord, L.I., Öhrlund, Å., Lärkner, H. and Kenne, A.H., 2012. Gel properties of hyaluronic acid dermal fillers. *Dermatologic Surgery*, 38(7pt2), pp.1170-1179.
18. Kablik, J., Monheit, G.D., Yu, L., Chang, G. and 18. Gershkovich, J., 2009. Comparative physical properties of hyaluronic acid dermal fillers. *Dermatologic Surgery*, 35, pp.302-312.
19. Talarico, S., Meski, A.P., Buratini, L., Manela-Azulay, M., Simpson, H., Sidou, F. and Kerrouche, N., 2015. High patient satisfaction of a hyaluronic acid filler producing enduring full-facial volume restoration: an 18-month open multicenter study. *Dermatologic Surgery*, 41(12), pp.1361-1369.
20. Philipp-Dormston, W.G., Wong, C., Schuster, B., Larsson, M.K. and Podda, M., 2018. Evaluating perceived naturalness of facial expression after fillers to the nasolabial folds and lower face with standardized video and photography. *Dermatologic Surgery*, 44(6), p.826.
21. Hilton, S., Sattler, G., Berg, A.K., Samuelson, U. and Wong, C., 2018. Randomized, evaluator-blinded study comparing safety and effect of two hyaluronic acid gels for lips enhancement. *Dermatologic Surgery*, 44(2), p.261.
22. Jones, D., Baumann, L., Moradi, A., Shridharani, S., Palm, M., Teller, C., Taylor, M., Kontis, T.C., Chapas, A., Kaminer, M.S. and Bank, D., 2021. A Randomized, Comparator-Controlled Study of HARC for Cheek Augmentation and Correction of Midface Contour Deficiencies. *Journal of Drugs in Dermatology: JDD*, 20(9), pp.949-956.
23. Huang, S.H. and Tsai, T.F., 2020. Safety and Effectiveness of Hyaluronic Acid Fillers With Lidocaine for Full-Face Treatment in Asian Patients. *Journal of Drugs in Dermatology: JDD*, 19(9), pp.836-842.
24. Narins, R.S., Brandt, F.S., Dayan, S.H. and Hornfeldt, C.S., 2011. Persistence of nasolabial fold correction with a hyaluronic acid dermal filler with retreatment: results of an 18 month extension study. *Dermatologic surgery*, 37(5), pp.644-650.
25. Percec, I., Bertucci, V., Solish, N., Wagner, T., Nogueira, A. and Mashburn, J., 2020. An objective, quantitative, dynamic assessment of hyaluronic acid fillers that adapt to facial movement. *Plastic and Reconstructive Surgery*, 145(2), p.295.
26. Galderma. Data on File. MA-48087.
27. Galderma. Data on File. MA-39680.
28. Kerscher, M., Bayrhammer, J. and Reuther, T., 2008. Rejuvenating influence of a stabilized hyaluronic acid-based gel of nonanimal origin on facial skin aging. *Dermatologic surgery*, 34(5), pp.720-726.
29. Taylor, S.C., Burgess, C.M. and Callender, V.D., 2009. Safety of nonanimal stabilized hyaluronic acid dermal fillers in patients with skin of color: a randomized, evaluator blinded comparative trial. *Dermatologic surgery*, 35, pp.1653-1660.
30. Cohen, J.L., Hicks, J., Nogueira, A., Lane, V. and Andriopoulos, B., 2022. Postmarket Safety Surveillance of Delayed Complications for Recent FDA-Approved Hyaluronic Acid Dermal Fillers. *Dermatologic Surgery*, 48(2), p.220.
31. Galderma. Data on File. MA-48544
32. Andriopoulos B et al. Poster presented at Aesthetic & Anti-aging Medicine World Congress. 4-6 April 2019. Monte Carlo, Monaco.
33. Narins, R.S., Dayan, S.H., Brandt, F.S. and Baldwin, E.K., 2008. Persistence and improvement of nasolabial fold correction with nonanimal stabilized hyaluronic acid 100,000 gel particles/mL filler on two retreatment schedules: results up to 18 months on two retreatment schedules. *Dermatologic surgery*, 34, pp.S2-S8.
34. Weiss, R., Beer, K., Cox, S.E., Palm, M., Kaufman-Janette, J., Bassichis, B., Biesman, B., Joseph, J., Almegård, B., Nilsson, A. and Edwartz, C., 2021. A randomized, controlled, evaluator-blinded, multi-center study of hyaluronic acid filler effectiveness and safety in lip fullness augmentation. *Dermatologic Surgery*, 47(4), p.527.
35. Restylane - search results - pubmed (no date) National Center for Biotechnology Information. U.S. National Library of Medicine. Available at: <https://pubmed.ncbi.nlm.nih.gov/?term=restylane> (Accessed: January 16, 2023).
36. Galderma. Data on File. MA-43602.
37. Rao, V., Chi, S. and Woodward, J., 2014. Reversing facial fillers: interactions between hyaluronidase and commercially available hyaluronic-acid based fillers. *Journal of Drugs in Dermatology: JDD*, 13(9), pp.1053-1056.
38. Sadeghpour, M., Quatrano, N.A., Bonati, L.M., Arndt, K.A., Dover, J.S. and Kaminer, M.S., 2019. Delayed-onset nodules to differentially crosslinked hyaluronic acids: comparative incidence and risk assessment. *Dermatologic Surgery*, 45(8), pp.1085-1094.
39. Di Gregorio, C., Gauglitz, G. and Partridge, J., 2022. Individualized Treatment Algorithm Using Hyaluronic Acid Fillers for Lifting, Contouring and Volumizing the Midface. *Clinical, Cosmetic and Investigational Dermatology*, 15, p.681.
40. Gubanov et al. Poster presented at the International Master Course on Aging Skin. 29 Jan-1 Feb 2015. Paris, France.
41. Nikolis A et al. Poster presented at the 20th Aesthetic & Anti-aging Medicine World Congress. 31 March-2 April 2022. Monte Carlo, Monaco.
42. Lundgren, B., Sandkvist, U., Bordier, N. and Gauthier, B., 2018. Using a New Photo Scale to Compare Product Integration of Different Hyaluronan-Based Fillers After Injection in Human Ex Vivo Skin. *Journal of drugs in dermatology: JDD*, 17(9), pp.982-986.
43. Galderma. Data on File. MA-42769.
44. Seo, K. (2021) "Facial Volumization with Fillers". doi: 10.1007/978-981-33-6212-3.
45. Segura, S., Anthonioz, L., Fuchez, F. and Herbage, B., 2012. A complete range of hyaluronic acid filler with distinctive physical properties specifically designed for optimal tissue adaptations. *Journal of Drugs in Dermatology: JDD*, 11(1 Suppl), pp.s5-8.
46. PMA P170002: FDA Summary of Safety and Effectiveness Data. 2017.
47. Bertucci, V., Nikolis, A., Solish, N., Lane, V. and Hicks, J., 2021. Subject and partner satisfaction with lip and perioral enhancement using flexible hyaluronic acid fillers. *Journal of Cosmetic Dermatology*, 20(5), pp.1499-1504.
48. Bertucci, V., Nikolis, A., Solish, N., Lane, V. and Hicks, J., 2021. Efficacy and Safety of Flexible Hyaluronic Acid Fillers in Lip and Perioral Enhancement. *Journal of Drugs in Dermatology: JDD*, 20(4), pp.402-408.
49. Kestemont, P., Cartier, H., Trevidic, P., Rzany, B., Sattler, G., Kerrouche, N. and Dhuin, J.C., 2012. Sustained efficacy and high patient satisfaction after cheek enhancement with a new hyaluronic acid dermal filler. *Journal of drugs in dermatology: JDD*, 11(1 Suppl), pp.s9-16.
50. Rogerio, V., Vieira, M.G., Rabelo, V., Carbone, A.C., Machado Filho, D.A., Da Silva, A.M. and De la Torre Canales, G., 2022. Features to consider for mimicking tissues in orofacial aesthetics with optimal balance technology and non-animal stabilized hyaluronic acid (Restylane®): The MIMT concept. *Journal of Stomatology, Oral and Maxillofacial Surgery*, 123(4), pp.440-447.
51. PMA P140029/S029: FDA Summary of Safety and Effectiveness Data. 2021.
52. Data on File. MA-22124.
53. Philipp Dormston, W.G., Schuster, B. and Podda, M., 2020. Perceived naturalness of facial expression after hyaluronic acid filler injection in nasolabial folds and lower face. *Journal of Cosmetic Dermatology*, 19(7), pp.1600-1606.
54. Solish, N., Bertucci, V., Percec, I., Wagner, T., Nogueira, A. and Mashburn, J., 2019. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. *Journal of Cosmetic Dermatology*, 18(3), pp.738-746.
55. Philipp-Dormston W et al. Poster presented at the Aesthetic & Anti-aging Medicine World Congress. 6-8 April 2017. Monaco.
56. Ascher, B., Bayerl, C., Kestemont, P., Rzany, B., Edwartz, C. and Podda, M., 2017. A 12-month follow-up, randomized comparison of effectiveness and safety of two hyaluronic acid fillers for treatment of severe nasolabial folds. *Dermatologic Surgery*, 43(3), p.389.
57. Marcus, K., Moradi, A., Kaufman-Janette, J., Ablon, G., Donofrio, L., Chapas, A., Kazin, R., Rivkin, A., Rohrich, R.J., Weiss, R. and George, R., 2022. A Randomized Trial to Assess Effectiveness and Safety of a Hyaluronic Acid Filler for Chin Augmentation and Correction of Chin Retrusion. *Plastic and Reconstructive Surgery*, 150(6), pp.1240e-1248e..
58. Rohrich, R.J., Bartlett, E.L. and Dayan, E., 2019. Practical approach and safety of hyaluronic acid fillers. *Plastic and Reconstructive Surgery Global Open*, 7(6).
59. Galderma. Data on File. W2O Quick Pulse Survey. 2020
60. Restylane® Injectable Gel. Summary of safety and effectiveness data (SSED). Available at: [www.accessdata.fda.gov/cdrh\\_docs/pdf2/P020023b.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf2/P020023b.pdf) (accessed November 2022).

# REFERENCES

61. Friedman, P.M., Mafong, E.A., Kauvar, A.N. and Geronemus, R.G., 2002. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. *Dermatologic Surgery*, 28(6), pp.491-494.
62. Weiss, R., Bank, D. and Brandt, F., 2010. Randomized, double blind, split face study of small gel particle hyaluronic acid with and without lidocaine during correction of nasolabial folds. *Dermatologic Surgery*, 36, pp.750-759.
63. Wu, Y., Tian, Y., Xu, J., Zhong, S., Wang, R. and Wu, W., 2020. A randomized study showing improved skin quality and aesthetic appearance of dorsal hands after hyaluronic acid gel treatment in a Chinese population. *Journal of Cosmetic Dermatology*, 19(7), pp.1627-1635.
64. Williams, S., Tamburic, S., Stensvik, H. and Weber, M., 2009. Changes in skin physiology and clinical appearance after microdroplet placement of hyaluronic acid in aging hands. *Journal of Cosmetic Dermatology*, 8(3), pp.216-225.
65. Gubanova, E.I., Starovatova, P.A. and Rodina, M.Y., 2015. 12-month effects of stabilized hyaluronic acid gel compared with saline for rejuvenation of aging hands. *Journal of drugs in dermatology: JDD*, 14(3), pp.288-298.
66. Dierickx, C., Larsson, M.K. and Blomster, S., 2018. Effectiveness and safety of acne scar treatment with nonanimal stabilized hyaluronic acid gel. *Dermatologic Surgery*, 44, pp.S10-S18.
67. Lee, B.M., Han, D.G. and Choi, W.S., 2015. Rejuvenating effects of facial hydrofilling using restylane vital. *Archives of plastic surgery*, 42(03), pp.282-287.
68. Ribé, A. and Ribé, N., 2011. Neck skin rejuvenation: histological and clinical changes after combined therapy with a fractional non-ablative laser and stabilized hyaluronic acid-based gel of non-animal origin. *Journal of Cosmetic and Laser Therapy*, 13(4), pp.154-161.
69. Kim, J., 2014. Effects of Injection Depth and Volume of Stabilized Hyaluronic Acid in Human Dermis on Skin Texture, Hydration, and Thickness. *Archives of Aesthetic Plastic Surgery*, 20(2), pp.97-103.
70. Magda Belmontesi, M.D., Francesca De Angelis, M.D., Carlo Di Gregorio, M.D. and Ivano Iozzo, M.D., 2018. Injectable non-animal stabilized hyaluronic acid as a skin quality booster: an expert panel consensus. *Journal of Drugs in Dermatology*, 17(1), pp.83-88.
71. Allergan Launches Juvéderm Volite - Modern Aesthetics (2023). Available at: <https://modernaesthetics.com/news/allergan-launches-juvderm-volite> (Accessed: 16 January 2023).
72. Profhilo | IBSA Nordic (2023). Available at: <https://www.ibsanordic.com/products/profhilo.html> (Accessed: 16 January 2023).
73. Galderma. Data on File. MA-39929.
74. GUBANOVA, Y.I., DIYACHENKO, Y.Y., RODINA, M.Y. and KOLIYEVA, M.K., 2010. Brand-new Hydrobalance technology on the basis of stabilized hyaluronic acid for long-term skin hydration. *Vestnik dermatologii i venerologii*, 86(1), pp.94-98.
75. Aesthetics Journal (2023). Available at: <https://aestheticsjournal.com/news/restylane-skinboosters-smartclick-delivery-system-wins-red-dot-award> (Accessed: 17 January 2023).
76. Dot, R. (2023) Red Dot Design Award: SmartClick™ System, Red-dot.org. Available at: <https://www.red-dot.org/project/smartclicktm-system-32176> (Accessed: 17 January 2023).
77. Nikolis, A., Berros, P., Enright, K.M., Cordoba, M. and Nguyen, Q., 2022. A randomized, crossover-controlled evaluator-blinded trial evaluating cannula-vs needle-assisted hyaluronic acid injections for infraorbital deformities. *Aesthetic Surgery Journal*, 42(3), pp.285-297.

Restylane®  
by GALDERMA



WITH THE **WORLD'S MOST DIVERSE RANGE OF INDIVIDUALLY ENGINEERED HYALURONIC ACID FILLERS AND SKINBOOSTERS**, RESTYLANE GIVES YOU UNPRECEDENTED CONTROL FOR YOUR ARTISTRY.\*<sup>1-11</sup>



The original HA filler with **MINIMAL MODIFICATION** – closest to skin's own HA for individualized and natural-looking results<sup>12-17</sup>



**HIGH PERFORMANCE** – less product for great effect and results that last up to 24 months<sup>18-20</sup>



**EXPERTS IN FACIAL DYNAMICS** – the first HA fillers clinically proven to have positive effects on the naturalness of dynamic facial expressions<sup>17,21</sup>



**PROVEN SAFETY** – unmatched 26 years of proven safety for diverse skin colors and types<sup>\*\*+20,22-25</sup>



**HIGH PATIENT SATISFACTION** across 26 years, with 55 million treatments worldwide<sup>\*\*25,26</sup>

\* The Restylane product family has a broader range in G' (elastic modulus) than Juvéderm, Belotero, and Teosyal.<sup>12</sup> G' is a measure of gel firmness (resistance to deformation), which can be used to understand how a gel's physical properties relate to its in vivo performance.<sup>12</sup>

\*\* Restylane injectable gel (also known as Restylane) was first approved for marketing and sale in September 1996 in the EU.<sup>25</sup>

† Based on a Restylane publications analysis conducted in June 2021. Sources include a published post-marketing safety study of 638 patients and a retrospective analysis of adverse event reports encompassing 406,000 patients.<sup>24</sup>

EU, European Union; HA, hyaluronic acid.

Restylane, Galderma, and NASHA are registered trademarks GL-RES-2200149 11/22